Immune Response—With Particular Reference to the Use of Multiple Antigens
The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inacti...
Gespeichert in:
Veröffentlicht in: | California medicine 1968-12, Vol.109 (6), p.452-457 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 457 |
---|---|
container_issue | 6 |
container_start_page | 452 |
container_title | California medicine |
container_volume | 109 |
creator | Wehrle, P F |
description | The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inactivated antigens may be given safely and with expectation of optimal effectiveness. dpt is a routine combination employed in combination with oral trivalent poliovaccine for primary immunization of infants and young children up to and including age six. Oral poliovirus vaccine and vaccinia may be administered at the time of the recall or booster dose of dpt vaccine during the second year of life, commonly at age 15 to 18 months. It is apparent from published data accumulated over many years that several antigens may be administered at the same time with adequate immunologic response. The minor differences in antibody response following simultaneous administration of live viral antigens is of unknown clinical importance. The primary reason for hesitancy in advocating greater use of multiple agents at this time is the theoretical consideration of possible neurotoxicity with those vaccines where the parent agent may have definite neurotoxicity. The question of possible additive or other harmful effects with measles, poliomyelitis, and rubella and mumps when given simultaneously can be answered only by carefully controlled studies involving close observation of the recipients with extension of these trials as data permit. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1503384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3994437111</sourcerecordid><originalsourceid>FETCH-LOGICAL-i327t-be3df3cee297972eb018da59405ec318735134bee3adc1bb0567aaa3c7f63783</originalsourceid><addsrcrecordid>eNpVkM1Kw0AUhYMotVYfQQi4DkwyM7mTjVCK2tr6g0S7HCbJTTs1TerMRHTnQ_iEPomBlqKru_gO3zncA68fUUGCJGHJodcnhIggjGJ27J1YuyKEARei5_U4REwA9L3pZL1ua_Sf0G6a2uLP1_dcu6X_qIzTeVsp06ESDdY5-q7x3RL9Z4t-U_p3beX0pkJ_WDu9wNqeekelqiye7e7AS6-v0tE4mD3cTEbDWaBpBC7IkBYlzRGjBBKIMCOhKBRPGOGY01AA5SFlGSJVRR5mGeExKKVoDmVMQdCBd7nVbtpsjUWOtTOqkhuj18p8ykZp-Z_UeikXzbsMOaFUsE5wsROY5q1F6-SqaU3dTZYhAI-IYAy61Pnfmr1_97qOB1uurcOPPVbmVcZAgcv7l5Ecz8gtzNOpTOkvtn98yw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1775208447</pqid></control><display><type>article</type><title>Immune Response—With Particular Reference to the Use of Multiple Antigens</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Wehrle, P F</creator><creatorcontrib>Wehrle, P F</creatorcontrib><description>The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inactivated antigens may be given safely and with expectation of optimal effectiveness. dpt is a routine combination employed in combination with oral trivalent poliovaccine for primary immunization of infants and young children up to and including age six. Oral poliovirus vaccine and vaccinia may be administered at the time of the recall or booster dose of dpt vaccine during the second year of life, commonly at age 15 to 18 months. It is apparent from published data accumulated over many years that several antigens may be administered at the same time with adequate immunologic response. The minor differences in antibody response following simultaneous administration of live viral antigens is of unknown clinical importance. The primary reason for hesitancy in advocating greater use of multiple agents at this time is the theoretical consideration of possible neurotoxicity with those vaccines where the parent agent may have definite neurotoxicity. The question of possible additive or other harmful effects with measles, poliomyelitis, and rubella and mumps when given simultaneously can be answered only by carefully controlled studies involving close observation of the recipients with extension of these trials as data permit.</description><identifier>ISSN: 0008-1264</identifier><identifier>EISSN: 2380-9949</identifier><identifier>PMID: 5724877</identifier><language>eng</language><publisher>United States: BMJ Publishing Group LTD</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Antibody Formation ; Antigen-Antibody Reactions ; Antigens ; Child ; Child, Preschool ; Humans ; Immune Tolerance ; Immunization ; Infant ; Infant, Newborn ; Middle Aged ; Preventive Health Services ; Viral Vaccines - adverse effects</subject><ispartof>California medicine, 1968-12, Vol.109 (6), p.452-457</ispartof><rights>Copyright BMJ Publishing Group LTD Dec 1968</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5724877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wehrle, P F</creatorcontrib><title>Immune Response—With Particular Reference to the Use of Multiple Antigens</title><title>California medicine</title><addtitle>Calif Med</addtitle><description>The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inactivated antigens may be given safely and with expectation of optimal effectiveness. dpt is a routine combination employed in combination with oral trivalent poliovaccine for primary immunization of infants and young children up to and including age six. Oral poliovirus vaccine and vaccinia may be administered at the time of the recall or booster dose of dpt vaccine during the second year of life, commonly at age 15 to 18 months. It is apparent from published data accumulated over many years that several antigens may be administered at the same time with adequate immunologic response. The minor differences in antibody response following simultaneous administration of live viral antigens is of unknown clinical importance. The primary reason for hesitancy in advocating greater use of multiple agents at this time is the theoretical consideration of possible neurotoxicity with those vaccines where the parent agent may have definite neurotoxicity. The question of possible additive or other harmful effects with measles, poliomyelitis, and rubella and mumps when given simultaneously can be answered only by carefully controlled studies involving close observation of the recipients with extension of these trials as data permit.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antibody Formation</subject><subject>Antigen-Antibody Reactions</subject><subject>Antigens</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Immunization</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Middle Aged</subject><subject>Preventive Health Services</subject><subject>Viral Vaccines - adverse effects</subject><issn>0008-1264</issn><issn>2380-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1968</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkM1Kw0AUhYMotVYfQQi4DkwyM7mTjVCK2tr6g0S7HCbJTTs1TerMRHTnQ_iEPomBlqKru_gO3zncA68fUUGCJGHJodcnhIggjGJ27J1YuyKEARei5_U4REwA9L3pZL1ua_Sf0G6a2uLP1_dcu6X_qIzTeVsp06ESDdY5-q7x3RL9Z4t-U_p3beX0pkJ_WDu9wNqeekelqiye7e7AS6-v0tE4mD3cTEbDWaBpBC7IkBYlzRGjBBKIMCOhKBRPGOGY01AA5SFlGSJVRR5mGeExKKVoDmVMQdCBd7nVbtpsjUWOtTOqkhuj18p8ykZp-Z_UeikXzbsMOaFUsE5wsROY5q1F6-SqaU3dTZYhAI-IYAy61Pnfmr1_97qOB1uurcOPPVbmVcZAgcv7l5Ecz8gtzNOpTOkvtn98yw</recordid><startdate>196812</startdate><enddate>196812</enddate><creator>Wehrle, P F</creator><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>196812</creationdate><title>Immune Response—With Particular Reference to the Use of Multiple Antigens</title><author>Wehrle, P F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i327t-be3df3cee297972eb018da59405ec318735134bee3adc1bb0567aaa3c7f63783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1968</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antibody Formation</topic><topic>Antigen-Antibody Reactions</topic><topic>Antigens</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Immunization</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Middle Aged</topic><topic>Preventive Health Services</topic><topic>Viral Vaccines - adverse effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Wehrle, P F</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>California medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wehrle, P F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Response—With Particular Reference to the Use of Multiple Antigens</atitle><jtitle>California medicine</jtitle><addtitle>Calif Med</addtitle><date>1968-12</date><risdate>1968</risdate><volume>109</volume><issue>6</issue><spage>452</spage><epage>457</epage><pages>452-457</pages><issn>0008-1264</issn><eissn>2380-9949</eissn><abstract>The increasing demand for preventive child health services and the general increase in international travel compel greater attention to the use of multiple antigens, both inactivated and live, when administered simultaneously. It appears that with the preparations currently licensed, multiple inactivated antigens may be given safely and with expectation of optimal effectiveness. dpt is a routine combination employed in combination with oral trivalent poliovaccine for primary immunization of infants and young children up to and including age six. Oral poliovirus vaccine and vaccinia may be administered at the time of the recall or booster dose of dpt vaccine during the second year of life, commonly at age 15 to 18 months. It is apparent from published data accumulated over many years that several antigens may be administered at the same time with adequate immunologic response. The minor differences in antibody response following simultaneous administration of live viral antigens is of unknown clinical importance. The primary reason for hesitancy in advocating greater use of multiple agents at this time is the theoretical consideration of possible neurotoxicity with those vaccines where the parent agent may have definite neurotoxicity. The question of possible additive or other harmful effects with measles, poliomyelitis, and rubella and mumps when given simultaneously can be answered only by carefully controlled studies involving close observation of the recipients with extension of these trials as data permit.</abstract><cop>United States</cop><pub>BMJ Publishing Group LTD</pub><pmid>5724877</pmid><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-1264 |
ispartof | California medicine, 1968-12, Vol.109 (6), p.452-457 |
issn | 0008-1264 2380-9949 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1503384 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adolescent Adult Age Factors Aged Antibody Formation Antigen-Antibody Reactions Antigens Child Child, Preschool Humans Immune Tolerance Immunization Infant Infant, Newborn Middle Aged Preventive Health Services Viral Vaccines - adverse effects |
title | Immune Response—With Particular Reference to the Use of Multiple Antigens |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T22%3A38%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Response%E2%80%94With%20Particular%20Reference%20to%20the%20Use%20of%20Multiple%20Antigens&rft.jtitle=California%20medicine&rft.au=Wehrle,%20P%20F&rft.date=1968-12&rft.volume=109&rft.issue=6&rft.spage=452&rft.epage=457&rft.pages=452-457&rft.issn=0008-1264&rft.eissn=2380-9949&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E3994437111%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1775208447&rft_id=info:pmid/5724877&rfr_iscdi=true |